GlassScriptPhysician profile
Donna M Burton
NPI 1457740565
$1,507.18
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $467 · 2022: $426 · 2023: $479 · 2024: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $615.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $496.27 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $388.90 | 2021-2024 | Dupixent |
| Glaxosmithkline, LLC. | $385.74 | 2021-2024 | Nucala |
| Optinose US, INC. | $50.39 | 2021-2022 | |
| Acclarent, INC | $34.04 | 2022 | |
| Amgen INC. | $23.94 | 2021 | |
| Alk-Abello, INC | $22.46 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.86 | 2021 | |
| Merck Sharp & Dohme LLC | $18.96 | 2023 | |
| Kaleo, INC. | $14.36 | 2021 | |
| Pfizer INC. | $14.27 | 2023 | |
| Stryker Corporation | $13.00 | 2022 | |
| Hikma Pharmaceuticals USA | $12.81 | 2023 | Ryaltris |
| Biohaven Pharmaceutical Holding Company LTD. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Burton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.